EXG115

EXG115 is an investigational biologic therapeutic, likely a monoclonal antibody, being developed by Exegenesis Bio for the treatment of Alzheimer's disease. The drug is designed to target the tau protein, a microtubule-associated protein that forms pathological aggregates known as neurofibrillary tangles, which are a hallmark of Alzheimer's disease and correlate with neurodegeneration and cognitive decline. By targeting tau, EXG115 aims to reduce tau-mediated pathology and potentially slow the progression of the disease. The program is currently in the IND-enabling stage of development and is intended for administration via intravenous or subcutaneous routes.